A study in the Journal of Nuclear Medicine suggests that using FDG PET/CT to measure metabolic tumor volume may predict survival of patients with osteosarcoma of the extremities and be useful in clinical decision making. Researchers analyzed FDG PET/CT scans of 83 patients who had been treated with chemotherapy and surgery, finding that the MTV using a 2.0 uptake value threshold predicted metastasis risk and poor therapeutic response.

Related Summaries